PT3042658T - Medicinal composition improving leptin resistance - Google Patents
Medicinal composition improving leptin resistanceInfo
- Publication number
- PT3042658T PT3042658T PT14843063T PT14843063T PT3042658T PT 3042658 T PT3042658 T PT 3042658T PT 14843063 T PT14843063 T PT 14843063T PT 14843063 T PT14843063 T PT 14843063T PT 3042658 T PT3042658 T PT 3042658T
- Authority
- PT
- Portugal
- Prior art keywords
- medicinal composition
- leptin resistance
- composition improving
- improving leptin
- resistance
- Prior art date
Links
- 102000016267 Leptin Human genes 0.000 title 1
- 108010092277 Leptin Proteins 0.000 title 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title 1
- 229940039781 leptin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
- C07C245/10—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013183265 | 2013-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3042658T true PT3042658T (en) | 2019-05-13 |
Family
ID=52628448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT14843063T PT3042658T (en) | 2013-09-04 | 2014-09-03 | Medicinal composition improving leptin resistance |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9931351B2 (en) |
| EP (1) | EP3042658B1 (en) |
| JP (1) | JP6378685B2 (en) |
| DK (1) | DK3042658T3 (en) |
| ES (1) | ES2708577T3 (en) |
| PL (1) | PL3042658T3 (en) |
| PT (1) | PT3042658T (en) |
| WO (1) | WO2015033981A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12011438B2 (en) | 2018-04-16 | 2024-06-18 | Kyoto University | Composition for protecting cardiomyocyte |
| JP7101982B2 (en) | 2018-07-31 | 2022-07-19 | 国立大学法人京都大学 | Pharmaceutical composition for the treatment of cerebral infarction |
| KR20220087499A (en) | 2019-10-24 | 2022-06-24 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Pharmaceutical composition for cartilage protection |
| JP7705649B2 (en) | 2021-04-28 | 2025-07-10 | 国立大学法人京都大学 | Composition for improving abnormalities in skin tissue |
| CN118434418A (en) | 2021-12-24 | 2024-08-02 | 国立大学法人京都大学 | Composition for improving heart function |
| KR20250093323A (en) * | 2022-10-27 | 2025-06-24 | 가부시키가이샤 교토 소야쿠 겐큐쇼 | Determination of naphthalene derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0679088T3 (en) | 1992-09-29 | 2002-10-28 | Inhale Therapeutic Syst | Pulmonary delivery of active fragments of parathyroid hormone |
| CN1158290C (en) | 1996-01-17 | 2004-07-21 | 诺沃挪第克公司 | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| IL133604A0 (en) | 1997-07-16 | 2001-04-30 | Novo Nordisk As | Fused 1, 2, 4-thiadiazine derivatives, their preparation and use |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| WO2007041282A2 (en) | 2005-09-29 | 2007-04-12 | The Johns Hopkins University | Methods and compositions for treatment of cystic fibrosis |
| PT2599771T (en) * | 2010-07-30 | 2016-12-14 | Univ Kyoto | Naphthalene derivative |
| EP2623494B1 (en) | 2010-09-30 | 2015-09-02 | Daito Chemix Corporation | Agent for treatment of eye diseases |
| BR112015001213A2 (en) | 2012-07-20 | 2018-05-22 | Cleave Biosciences Inc | fused pyrimidines as p97 complex inhibitors |
| US9782420B2 (en) | 2013-02-20 | 2017-10-10 | Kyoto University | Method for treating eye diseases |
-
2014
- 2014-09-03 PT PT14843063T patent/PT3042658T/en unknown
- 2014-09-03 JP JP2015535505A patent/JP6378685B2/en not_active Expired - Fee Related
- 2014-09-03 ES ES14843063T patent/ES2708577T3/en active Active
- 2014-09-03 PL PL14843063T patent/PL3042658T3/en unknown
- 2014-09-03 DK DK14843063.0T patent/DK3042658T3/en active
- 2014-09-03 US US14/916,085 patent/US9931351B2/en active Active
- 2014-09-03 WO PCT/JP2014/073256 patent/WO2015033981A1/en not_active Ceased
- 2014-09-03 EP EP14843063.0A patent/EP3042658B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2015033981A1 (en) | 2017-03-02 |
| WO2015033981A1 (en) | 2015-03-12 |
| PL3042658T3 (en) | 2019-08-30 |
| EP3042658A1 (en) | 2016-07-13 |
| ES2708577T3 (en) | 2019-04-10 |
| US9931351B2 (en) | 2018-04-03 |
| US20160303144A1 (en) | 2016-10-20 |
| DK3042658T3 (en) | 2019-04-23 |
| EP3042658B1 (en) | 2019-01-16 |
| EP3042658A4 (en) | 2017-03-29 |
| JP6378685B2 (en) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286759A (en) | Therapeutic methods and compositions | |
| ZA201506487B (en) | Therapeutic compounds and compositions | |
| IL246377A0 (en) | Oral pharmaceutical composition | |
| GB201317286D0 (en) | Composition and Use | |
| SG11201508167PA (en) | Therapeutic compositions and uses thereof | |
| IL241254A0 (en) | Pharmaceutical compositions comprising everolimus | |
| ZA201403276B (en) | Low dose pharmaceutical composition | |
| EP3006525A4 (en) | Asphalt-urethane composition | |
| GB201318489D0 (en) | Composition | |
| SG11201510442TA (en) | Oral composition | |
| GB201317388D0 (en) | Composition | |
| GB201306984D0 (en) | Composition | |
| PT3042658T (en) | Medicinal composition improving leptin resistance | |
| GB201317196D0 (en) | Composition | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| TWI562776B (en) | Pharmaceutical composition and uses thereof | |
| GB201307622D0 (en) | Composition | |
| SG11201506778QA (en) | Plasticizing composition | |
| GB201308933D0 (en) | Paediatric composition | |
| GB201301979D0 (en) | New composition and use thereof | |
| EP2977051A4 (en) | Ginsenoside composition | |
| GB201308502D0 (en) | Composition | |
| GB201301774D0 (en) | Composition | |
| IL244365A0 (en) | Pharmaceutical composition | |
| GB201318394D0 (en) | Composition |